PUBLIC COMPANY
saveEyebiotech Ltd
updated 3mo ago
community read0 votes
🐶 often sniffed alongside
top 3pipeline
1
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
- phase3A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
- phase3A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
- phase2A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
- phase3A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
- phase2A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
- phase2A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO
🐶 Hiring Signal
News
no news has mentioned this company yet
comments(0)
5-min edit window · permanent after that